159 related articles for article (PubMed ID: 38503825)
1. Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.
Wang C; Zhao Z; Zhao Y; Zhao J; Xia L; Xia Q
Commun Biol; 2024 Mar; 7(1):342. PubMed ID: 38503825
[TBL] [Abstract][Full Text] [Related]
2. Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.
Qiao MX; Li C; Zhang AQ; Hou LL; Yang J; Hu HG
Oncol Rep; 2016 Oct; 36(4):2382-90. PubMed ID: 27499261
[TBL] [Abstract][Full Text] [Related]
3. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.
Chen G; Wang Y; Zhao X; Xie XZ; Zhao JG; Deng T; Chen ZY; Chen HB; Tong YF; Yang Z; Ding XW; Guo PY; Yu HT; Wu LJ; Zhang SN; Zhu QD; Li JJ; Shan YF; Yu FX; Yu ZP; Xia JL
J Exp Clin Cancer Res; 2021 Jun; 40(1):218. PubMed ID: 34193219
[TBL] [Abstract][Full Text] [Related]
4. [VIPR1 promoter methylation promotes transcription factor AP-2
Ning S; He C; Guo Z; Zhang H; Mo Z
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jul; 42(7):957-965. PubMed ID: 35869757
[TBL] [Abstract][Full Text] [Related]
5. AP-2α inhibits hepatocellular carcinoma cell growth and migration.
Huang W; Chen C; Liang Z; Qiu J; Li X; Hu X; Xiang S; Ding X; Zhang J
Int J Oncol; 2016 Mar; 48(3):1125-34. PubMed ID: 26780928
[TBL] [Abstract][Full Text] [Related]
6. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
[TBL] [Abstract][Full Text] [Related]
7. Involvement of DNA damage response pathways in hepatocellular carcinoma.
Yang SF; Chang CW; Wei RJ; Shiue YL; Wang SN; Yeh YT
Biomed Res Int; 2014; 2014():153867. PubMed ID: 24877058
[TBL] [Abstract][Full Text] [Related]
8. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Lin YT; Chao CC
Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
[TBL] [Abstract][Full Text] [Related]
9. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
10. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.
Wang J; McGrail DJ; Bhupal PK; Zhang W; Lin KY; Ku YH; Lin T; Wu H; Tsai KC; Li K; Peng CY; Finegold MJ; Lin SY; Tsai RYL
Mol Cancer Res; 2020 May; 18(5):723-734. PubMed ID: 32051231
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA CCAL promotes hepatocellular carcinoma progression by regulating AP-2α and Wnt/β-catenin pathway.
Liu Y; Yang Y; Wang T; Wang L; Wang X; Li T; Shi Y; Wang Y
Int J Biol Macromol; 2018 Apr; 109():424-434. PubMed ID: 29275200
[TBL] [Abstract][Full Text] [Related]
12. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
Cheng BY; Lau EY; Leung HW; Leung CO; Ho NP; Gurung S; Cheng LK; Lin CH; Lo RC; Ma S; Ng IO; Lee TK
Cancer Res; 2018 May; 78(9):2332-2342. PubMed ID: 29483095
[TBL] [Abstract][Full Text] [Related]
13. Transcription Factor E2F8 Promotes Cisplatin Resistance in Hepatocellular Carcinoma by Regulating DNA Damage via NUSAP1.
Kong J; Xu S; Zhang P; Wang Y
Int J Toxicol; 2023; 42(5):420-429. PubMed ID: 37331996
[TBL] [Abstract][Full Text] [Related]
14. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
15. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features.
Lin P; Gao RZ; Wen R; He Y; Yang H
Front Immunol; 2021; 12():715460. PubMed ID: 34456923
[TBL] [Abstract][Full Text] [Related]
16. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3ε mediates the cell fate decision-making pathways in response of hepatocellular carcinoma to Bleomycin-induced DNA damage.
Tang S; Bao H; Zhang Y; Yao J; Yang P; Chen X
PLoS One; 2013; 8(3):e55268. PubMed ID: 23472066
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of activating protein-4 regulated growth of hepatocellular carcinoma.
Ge Z; Zhang B; Bu X; Wang Y; Xiang L; Tan J
Tumour Biol; 2014 Dec; 35(12):12441-7. PubMed ID: 25195135
[TBL] [Abstract][Full Text] [Related]
19. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
20. NELF complex fosters BRCA1 and RAD51 recruitment to DNA damage sites and modulates sensitivity to PARP inhibition.
Bishara LA; Machour FE; Awwad SW; Ayoub N
DNA Repair (Amst); 2021 Jan; 97():103025. PubMed ID: 33248388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
